- Home
- GLPG vs BMEZ Comparison
GLPG vs BMEZ Comparison
Compare GLPG & BMEZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- BMEZ
- Stock Information
- Founded
- GLPG 1999
- BMEZ N/A
- Country
- GLPG Belgium
- BMEZ United States
- Employees
- GLPG N/A
- BMEZ N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- BMEZ Trusts Except Educational Religious and Charitable
- Sector
- GLPG Health Care
- BMEZ Finance
- Exchange
- GLPG Nasdaq
- BMEZ Nasdaq
- Market Cap
- GLPG 2.1B
- BMEZ 889.4M
- IPO Year
- GLPG 2005
- BMEZ N/A
- Fundamental
- Price
- GLPG $32.26
- BMEZ $14.24
- Analyst Decision
- GLPG Sell
- BMEZ
- Analyst Count
- GLPG 4
- BMEZ 0
- Target Price
- GLPG $25.33
- BMEZ N/A
- AVG Volume (30 Days)
- GLPG 168.5K
- BMEZ 391.3K
- Earning Date
- GLPG 10-29-2025
- BMEZ 01-01-0001
- Dividend Yield
- GLPG N/A
- BMEZ 8.71%
- EPS Growth
- GLPG N/A
- BMEZ N/A
- EPS
- GLPG N/A
- BMEZ 0.54
- Revenue
- GLPG $323,674,692.00
- BMEZ N/A
- Revenue This Year
- GLPG N/A
- BMEZ N/A
- Revenue Next Year
- GLPG N/A
- BMEZ N/A
- P/E Ratio
- GLPG N/A
- BMEZ $30.17
- Revenue Growth
- GLPG 5.43
- BMEZ N/A
- 52 Week Low
- GLPG $22.36
- BMEZ $12.93
- 52 Week High
- GLPG $33.86
- BMEZ $16.95
- Technical
- Relative Strength Index (RSI)
- GLPG 51.29
- BMEZ 49.65
- Support Level
- GLPG $31.49
- BMEZ $13.82
- Resistance Level
- GLPG $33.63
- BMEZ $14.64
- Average True Range (ATR)
- GLPG 0.66
- BMEZ 0.16
- MACD
- GLPG -0.06
- BMEZ -0.04
- Stochastic Oscillator
- GLPG 50.18
- BMEZ 50.00
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.